MorphoSys AG (MOR) 2013年年度报告「NASDAQ」.pdf

1、ANNUAL REPORT 2013theofProduct PipelineMorphoSyss Product Pipeline,as of 31 December 2013ProgramPartnerIndIcatIonPhase 1Phase 2Phase 3marketMOR103GSKRheumatoid arthritis Multiple sclerosis MOR208UnpartneredChronic lymphocytic leukemia Acute lymphoblastic leukemia Non-Hodgkins lymphoma MOR202CelgeneM

2、ultiple myeloma BimagrumabNovartisSporadic inclusion body myositis Cachexia(cancer)Sarcopenia Mechanically ventilated patients Cachexia(chronic obstructive pulmonary disease)GantenerumabRocheProdromal Alzheimers disease Genetically predisposed for Alzheimers disease Japanese Alzheimers disease patie

3、nts CNTO3157JanssenAsthma Safety/pharmacokinetic CNTO6785JanssenChronic obstructive pulmonary disease Rheumatoid arthritis GuselkumabJanssenPsoriasis Rheumatoid arthritis Palmoplantar pustulosis BHQ880NovartisMultiple myeloma(with renal insufficiency)Smoldering multiple myeloma LFG316NovartisWet age

4、-related macular degeneration Age-related macular degeneration Multifocal choroiditis and panuveitis LJM716 NovartisEsophageal squamous cell carcinoma HER2+Cancer HER2+Cancer(combination with trastuzumab)Solid tumors NOV-3 Novartisn.d.VAY736 NovartisPemphigus vulgaris OMP-59R5 OncomedPancreatic canc

5、er Small cell lung cancer Solid tumors BAY94-9343BayerSolid tumors BI-836845BICancer Cancer NOV-7NovartisEye disease VantictumabOncomedSolid tumors Breast cancer Non-small cell lung cancer PF-05082566PfizerCancer Additionally,MorphoSys currently has various proprietary and part-nered programs in the

6、 discovery or preclinical phase (31 Dec.2013:40 programs in dis-covery,22 programs in preclinic).legend:out-licensed to partner proprietary program co-development/co-promotion partnered programsEnginEEring the mEdicinEs of tomorrowmorphosys has built a reputation in the pharmaceutical industry as th